January 4th, 2009

Expectant Brains Help Predict Anxiety Treatment Success
A network of emotion-regulating brain regions implicated in the pathological worry that can grip patients with anxiety disorders may also be useful for predicting the benefits of treatment.
ScienceDaily - Jan. 4, 2009

A new study appearing online Jan. 2 reports that high levels of brain activity in an emotional center called the amygdala reflect patients’ hypersensitivity to anticipation of adverse events. At the same time, high activity in a regulatory region known as the anterior cingulate cortex is associated with a positive clinical response to a common antidepressant medication.

The study will appear in an upcoming issue of the American Journal of Psychiatry.

For individuals with anxiety disorders, the anticipation of a bad outcome can be worse than the outcome itself, says Jack Nitschke, assistant professor and clinical psychologist at the University of Wisconsin-Madison School of Medicine and Public Health and lead author of the new study. Some individuals spend so much time worrying about getting into a negative situation or having a panic attack, he says, that the condition becomes debilitating. “In an extreme situation, they might not even leave their home,” he says.

To study how the brain responds to anticipation, researchers at the UW-Madison Waisman Laboratory for Brain Imaging and Behavior used functional magnetic resonance imaging (fMRI) to examine patients with generalized anxiety disorder (GAD) as they viewed a set of negative and neutral images. Patients were shown pre-image cues several seconds before each picture so they would know what to expect: a circle before a neutral image and a minus sign before an aversive image.

While GAD patients showed no difference compared to healthy subjects in brain activation in response to the aversive or neutral pictures themselves, they displayed unusually high levels of amygdala activity in response to both anticipatory cues. According to Nitschke, the response suggests that the patients are hypersensitive to the anticipation of any stimuli, even those they are told will not be negative.

“In response to both of those anticipatory signals, the GAD subjects — the anxious folks — are showing huge amounts of amygdala activation that is much more than what healthy control subjects showed,” he says.

The researchers believe the high levels of amygdala activity seen in GAD patients reflects an indiscriminate and disproportionately large response to the idea that something negative might happen in the future, even in a lab setting where they know nothing bad will actually occur, he says.

“It suggests that there are differences in anticipatory brain processing in these individuals,” he says, adding that the result has important implications for other related disorders as well. “That’s the crux of what’s debilitating in people with anxiety disorders, whether it’s panic disorder, obsessive compulsive disorder or post-traumatic stress disorder.”

The patterns of brain activity also appear to hold predictive power for how patients will respond to treatment for their anxiety. After their brain scans, the GAD patients in the study received an eight-week course of treatment with venlafaxine (Effexor), a common antidepressant. Clinical improvement on the medication was associated with higher levels of pre-treatment brain activity in the anterior cingulate cortex (ACC) in anticipation of both aversive and neutral stimuli.

The ACC is a regulatory brain region important for modulating emotional responses. Activity in the same area has been shown to predict clinical outcome in patients with depression.

“When you look within the GAD patient population, that area is what predicts whether they respond to this treatment,” says Nitschke. “What it suggests is that people who still have some residual functioning of that area are the people who are more likely to get better” with this drug.

Choosing the most appropriate treatment approach for an individual patient is an important and difficult issue, he says, because anxiety disorders encompass a range of conditions with diverse symptoms and causes. Anxiety disorders are also frequently associated with depression, and Nitschke and his collaborators next plan to examine GAD patients with and without major depressive disorder.

“This is a critical new direction that the field is already moving in — using fMRI to predict treatment response,” he says. “Hopefully we’ll be able to use that eventually to determine what kind of treatment to provide to people.”"

Popularity: 41% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...
November 28th, 2008

So, this is gradually turning into a sob session of a blog. I have been checking for new information but everyone is so concerned with the economy of the US as well as the rest of the world that nobody is really focused on other issues. I will continue to check and update on you on any info as soon as some turns up.

As for my state today. I am feeling a little better than I was in my last post. I don’t have tears streaming down my face this time so that is a drastic improvement. I went to the psychiatrist only to find that it was an initial intake appointment and my actual evaluation is scheduled for February. Nice how concerned they are, right? I managed to convince my PCP to call something in for me to hold me over and she gave me a Rx for Xanax. It definitely helps with my panic attacks because I don’t tend to have them while I’m comatose but I can’t remember my dreams any more so who knows how I’m actually sleeping. I know that I’m out for 10-12 hours at a time and it takes me roughly an hour to be alert once I wake.

I have been reading a lot on various other blogs today about heartbreak and I guess I’m not totally alone in the way I feel. I even read a post from a lady discussing how the lack of the weight of her engagement ring on her hand was a constant physical reminder of the emptiness in her life. I know how she feels. I miss my ring; I still wear it when I’m home alone or sometimes when I’m sleeping. I have even left the house with it in my pocket and slipped it on once I was in the car, so D wouldn’t see, on more than a couple of occasions. I love the ring, I think it is the most elegant one I have ever seen. D’s name and our anniversary date are inscribed on the inside and I sometimes take it out and look at that inscription and think of all the dreams it represented. Even though it is a beautiful piece of jewelry, that is not why I love it so. I love that it was given to me as a token of his love and a promise of our future. I still can’t look at it and just see a ring. Maybe in time…

Popularity: 58% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...
November 15th, 2008

This is scary. As patients we depend on our doctors to explain the things that are happening to our bodies that we don’t understand. How can we find peace and proper treatment knowing that half of those responsible for caring for us are unable to adequately diagnose a person suffering from a panic attack. I am encouraged to see all of the studies and advancements (political, social, and medical) happening now but very dismayed to learn that so many physicians are still oblivious to the needs of patients with this condition.

BCM - Dipali Pathak
Panic Attacks Often Confused With Other Medical Issues

HOUSTON — (November 14, 2008) — The symptoms of panic attacks are frequently confused by physicians with other problems, indicating a need for better education in the area, said researchers at Baylor College of Medicine in Houston, who surveyed physicians on the topic. A report of their study appears in the online version of the Journal of Clinical Psychology in Medical Settings.
“Because symptoms of panic attacks can be confused with those of other medical problems related to the heart and gastrointestinal tract as well as neurological problems, a lack of knowledge about panic attacks can lead to unnecessary referrals and tests,” said Dr. Ellen Teng, assistant professor of psychiatry and behavioral sciences at BCM and clinical research psychologist at the Michael E. DeBakey Veterans Affairs Medical Center.
Survey responses
Researchers evaluated 95 surveys received from cardiologists, gastroenterologists and neurologists in the Houston area. The survey questions included information about those most at risk for panic attacks and treatment options.
The physicians answered only half of the survey questions about panic attacks correctly. There was no difference in knowledge among the three specialty groups.
While 94 percent recognized medication as a way to treat panic and anxiety symptoms, only about 30 percent recognized cognitive behavioral therapy to educate patients about panic attacks and their symptoms and give them tools to deal with the problem as the treatment of choice.
Long-term treatment
“Medication does treat the short-term aspects of panic attacks such as shortness of breath and a racing heart, but cognitive behavioral therapy treats panic disorder in the long-term,” said Teng.
Only slightly more than half of the physicians surveyed believed that psychologists could treat panic attacks directly and effectively through this technique.
Teng called for increased awareness of panic disorder among physicians. Teng also recommends providing resources and literature for physicians to make appropriate referrals to psychologists.
Symptoms of panic attack
Common symptoms of a panic attack include heart pounding, shortness of breath, light headedness and trembling. Panic disorder develops when several panic attacks occur out of the blue. Patients then worry about what the attack means and when the next one will take place, which may cause them to avoid certain places or events.
If a panic attack does occur for the first time, Teng recommends seeing a physician to rule out the risk of heart disease or another serious problem.
Others who took part in this research include Drs. Angelic D. Chaison, Sara D. Bailey, Joseph D. Hamilton and Nancy Jo Dunn, all of BCM and the Michael E. DeBakey Veterans Affairs Medical Center.
Funding for this work came from the South Central Mental Illness, Research, Education and Clinical Centers, a part of the United States Department of Veterans Affairs.
The study can be found at http://www.springerlink.com/content/q5718wm131242433/fulltext.pdf.”

Popularity: 45% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...
November 15th, 2008

Wall Street Journal - Market Watch
New Data, New Directions in the Management of Mood and Anxiety Disorders

VIENNA, Austria, November 14, 2008 /PRNewswire via COMTEX/ — - 8th International Forum for Mood and Anxiety Disorders Congress Roundup
Clinicians and researchers from around the world attended this week’s 8th International Forum on Mood and Anxiety disorders in Vienna, Austria to discuss the latest advances in the treatment of mood disorders.
A wide range of topics were included in this year’s programme, highlighting the position of IFMAD in the congress calendar as a forum for breaking news, original thinking and debate.
Highlights from the meeting included the latest new treatments for depression and anxiety disorders. There was the first comprehensive presentation of data demonstrating that quetiapine has clear cut efficacy in major depressive disorder (MDD), including a study in the elderly, a difficult to treat and under-researched patient population. It is also the first time that an antidepressant has shown consistent early efficacy at one week in both MDD and bipolar depression. Delegates were excited at the announcement at IFMAD of the first EU licence within the EU for a treatment for bipolar depression.
This year’s IFMAD reflected the rapid pace in which new discoveries are being made to improve our understanding of the mechanisms of mood disorders, the underlying neurobiology and the role of antidepressant treatment. Data evaluating a wide range of potential treatment directions were presented, including studies on the antidepressant agomelatine which targets melatonin and serotonin receptors in the brain. Other new data were presented showing that as much as 30 percent of unipolar depression has genetic or symptomatic predictors for the development of bipolar disorder and the delegates agreed that this was an important area for further research and the targeting of new treatments.
“We are living in exciting times for the treatment of mood disorders with new approaches and new targets being discovered and explored all of the time,” said Professor Siegfried Kasper, IFMAD Chairman and Professor of Psychiatry, Head of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. “The breadth of data presented at this year’s IFMAD has really demonstrated this, providing delegates with a comprehensive update of cutting edge advances in the field.”
Other elements of the meeting included an important debate on the relationships between pain, anxiety and depression and the continuing problem of under-diagnosis of GAD despite its prevalence and significant burden to society. The vital need to ensure patient concordance in the treatment of depression and anxiety was discussed, including the roles of patient education, monitoring and the selection of treatments with minimal side effects.
“The format of IFMAD allows informal debate and brings together leaders in the field of mood and anxiety disorders to discuss the most pressing topics and issues of the moment,” said Professor Stuart Montgomery, IFMAD Co-Chairman and Emeritus Professor of Psychiatry, Imperial College of Medicine, University of London, UK. “What sets IFMAD apart is that the meeting is friendly and small enough to allow that informal exchange of new and emerging data from around the world.”
This year’s meeting also marked the launch of the new IFMAD website, providing an online forum to ensure that clinicians and researchers can access the latest developments in mood disorders throughout the year. A full roundup of the 8th IFMAD meeting, including the final abstract book, will be available shortly on the new website, http://www.ifmad.org.
Notes to Editors
About IFMAD
IFMAD is a professional organisation dedicated to raising awareness of the latest international thinking and innovations in mood and anxiety disorders and promoting the exchange of ideas across the global psychiatric community.
IFMAD was founded in 2001 by Professor Siegfried Kasper and Professor Stuart Montgomery, supported by a scientific committee consisting of leading figures in mood and anxiety disorders from around the world.
IFMAD organises a yearly congress to promote debate and highlight the latest research in mood and anxiety disorders. Now in its ninth year, the annual event has become an important forum for the exchange of ideas and a key part of the congress calendar.
Sponsors of this year’s IFMAD meeting included H.Lundbeck A/S, who also supported the development of the new IFMAD website through an unrestricted educational grant, Astra Zeneca, Pierre Fabre Medicament, Servier and Wisepress Ltd.
SOURCE IFMAD ”

Popularity: 46% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...
November 13th, 2008

NEW YORK (AP) — The same kind of deep brain stimulation used to treat some patients for Parkinson’s disease also helped a few people suffering from obsessive-compulsive disorder, French scientists reported.

Their study involved only 16 patients, but in four of them, symptoms nearly disappeared. However, many patients had serious side effects, including one case of bleeding in the brain.

The treatment involved an experimental brain pacemaker, and it reduced repetitive thoughts and behaviors in some of the patients — just as it blocks tremors for some Parkinson’s sufferers.

The researchers came up with the approach after noticing that two Parkinson’s patients who got the treatment also saw an improvement to their obsessive-compulsive disorders. Other small studies have targeted a different part of the brain for that disorder and depression.

In the French study, symptoms were reduced more than 25 percent, the researchers said.

The results are “very encouraging,” said the study’s lead author, Dr. Luc Mallet of Pitie-Salpetriere Hospital in Paris. In an e-mail, he said the procedure should be used only in medical studies at the moment because of the possible side effects.

The findings are reported in Thursday’s New England Journal of Medicine.

About 2.2 million American adults have obsessive-compulsive disorder. It involves recurring, unwanted thoughts, such as a fear of germs, and people who have it engage in rituals such as repeatedly washing their hands or checking on something again and again.

Standard treatment, antidepressants and psychotherapy, doesn’t work in everyone. The patients in the French study were severe cases who didn’t respond well to treatment.

All had surgery to have the pacemaker — similar to a heart pacemaker — implanted in their chest and connected to electrodes inserted into their brains. Each patient had the pacemaker turned on for three months and turned off for three months. Neither the patients nor their doctors knew when the device was on or off.

The researchers used different tests to measure changes in symptoms. In one evaluation, after three months of stimulation, the severity of symptoms overall had dipped to 19 on a 40-point scale, compared to a score of 28 after three months of no treatment.

Eleven patients had serious side effects; one had bleeding in the brain and two had infections from the surgery. For some patients, the stimulation resulted in a mild form of mania and other problems that went away when adjustments were made.

Mallet said the area of the brain they targeted — the subthalamic nucleus — deals with motion, thinking and emotion. Previous studies for obsessive-compulsive disorder, or OCD, focused on regions involving mood and anxiety, he said.

“We’re still not exactly sure where the sweet spot is in the brain to reduce the symptoms of OCD,” said Dr. Wayne Goodman, a psychiatrist at the National Institute of Mental Health. “Even if you think you’re in the right neighborhood, you may be one block off. And one block off in the brain may be just 1 millimeter.”

Goodman said he was initially alarmed by the serious side effects but noted that many were temporary and others were not unexpected. He said the challenge will be deciding whether the risks are worth it for individual patients.

Another French researcher, Dr. Antoine Pelissolo, said the patients in the study, who now all have their pacemakers turned on, are still being followed. Researchers are also testing stimulating two areas of the brain at the same time, he said.

The pacemakers used in the study were bought from Medtronic Inc., which had no role but paid for the researchers’ meetings. Some of the scientists have received consulting fees and grants from Medtronic.”

Popularity: 44% [?]

Share This Post

Show Love (No Ratings Yet)
Loading ... Loading ...